An overview of candesartan in clinical practice

References

• Chobanian AV, Bakris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Weber M. Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes? Eur. Heart J.5(Suppl. C), C1–C4 (2003).
   Google Scholar
• Waeber B. Combination therapy with ACE inhibitors/angiotensinII receptor antagonists and diuretics in hypertension. Expert Rev. Cardiovasc. Ther.1(1), 43–50 (2003).
   PubMedGoogle Scholar
• Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med.122, 290–230 (2009).
   PubMed Web of Science ®Google Scholar
• Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE), a randomized, parallel-group trial. Lancet377(9762), 312–320 (2011).
   PubMed Web of Science ®Google Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The cycle repeats. Drugs62, 443–462 (2002).
   PubMed Web of Science ®Google Scholar
• Bakris GL. The importance of blood pressure control in the patient with diabetes. Am. J. Med.116, 30S–38S (2004).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), a multicentre randomized controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am. J. Hypertens.13(1 Pt 2), 18S–24S (2000).
   PubMed Web of Science ®Google Scholar
• Vanderheyden PML, Fierens FLP, Vauquelin G. Angiotensin II type 1receptor antagonists. Why do some of them produce insurmountable inhibition? Biochem. Pharmacol.60, 1557 (2000).
   Google Scholar
• Vauquelin G, Fierens FLP, Vanderheyden PML. Distinction between surmountable and insurmountable angiotensin II AT1 receptor antagonists. In: Angiotensin II Receptor Antagonists. Epstein M, Brunner HR, (Eds). Hanley and Belful, PA, USA, 105–118 (2000).
   Google Scholar
• Gleiter CH, Mörike K. Clinical pharmacokinetics of candesartan. Clin. Pharmacokinet.41, 7–17 (2002).
   PubMed Web of Science ®Google Scholar
• Van Liefde I, Vauquelin G. Sartan AT (1) receptor interaction: in vitro evidence for insurmountable antagonism and inverse agonsim. Mol. Cell Endocrinol.302(2), 237–243 (2009).
   PubMed Web of Science ®Google Scholar
• Sever P, Michel J, Voet B. Candesartan cilexitil (CC), A meta-analysis of time-to-effect relationship. Am. J. Hypertens.11(4 Pt 2), 79A (1998).
   Google Scholar
• Elmfeldt D, Olofsson B, Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press.11(5), 293–301 (2002).
   PubMed Web of Science ®Google Scholar
• Himmelmann A, Keinanen-Kiukaanniemi S, Wester A, Redon J, Asmar R, Hedner T. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press.10(1), 43–51 (2001).
   PubMed Web of Science ®Google Scholar
• Andersson OK, Neldam S. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J. Hum. Hypertens.11(Suppl. 2), S63–S64 (1997).
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/losartan study investigators. Am. J. Hypertens.12(12 Pt 1–2), 1181–1187 (1999).
   PubMed Web of Science ®Google Scholar
• Bönner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr. Med. Res. Opin.20(5), 597–602 (2004).
   PubMed Web of Science ®Google Scholar
• Azizi M, Nisse-Durgeat S, French Collaborative Group. Comparison of the antihypertensive effects of the candesartan 8 mg hydrochlorothiazide 12.5 mg combination vs. the valsartan 80 mg hydrochlorothiazide 12.5 mg combination in patients with essential hypertension resistant to monotherapy. [Abstract no. P2.367]. J. Hypertens.22(Suppl. 2), S254–S255 (2004).
   Google Scholar
• Uen S, Un I, Fimmers R, Vetter H, Mengden T. Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension. Deutsche Medizinische Wochenschrift132(3), 81–86 (2007).
   Google Scholar
• Edes I. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin. Drug Investig.29(5), 293–304 (2009).
   PubMed Web of Science ®Google Scholar
• Oparil S, Michelson EL. Long term efficacy, safety, and tolerability of candesartan cilexitil added to hydrochlorothiazide in patients with severe hypertension. Am. J. Hypertens.12, 120 (2009).
   Google Scholar
• Bramlage P, Schonrock E, Odoj P, Wolf WP, Funken C. Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ. MMW Fortschritte der Medizin.149(Suppl. 4), 172–181 (2008).
   PubMedGoogle Scholar
• Bönner G. Antihypertensive efficacy and tolerability of candesartan- hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press.17(Suppl. 2), 22–30 (2008).
   Web of Science ®Google Scholar
• Hasebe N, Kikuchi K; NICE Combi Study Group. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J. Hypertens.23(2), 445–453 (2005).
   PubMed Web of Science ®Google Scholar
• Papadopolous D, Makris T, Papademtriou V. Is it time to treat prehypertension? Hypertens Res.31(9), 1681–1686 (2008).
   PubMedGoogle Scholar
• Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med.354, 1685–1697 (2006).
   PubMed Web of Science ®Google Scholar
• Egan B, Nesbitt S, Julius S. Prehypertension: should we be treating with pharmacologic therapy? Ther. Adv. Cardiovasc. Dis.2(4), 305–314 (2008).
   PubMedGoogle Scholar
• Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program. Lancet362(9386), 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet362(9386), 767–771 (2003).
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet362(9386), 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet362(9386), 777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008, the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J.29(19), 2388–2442 (2008).
   PubMed Web of Science ®Google Scholar
• Lithell P, Hansson L, Skoog I et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE), principal results of a randomized double-blind intervention trial. J. Hypertens.21(5), 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D et al.; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll Cardiol.44(6), 1175–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kuschewski A et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke34(7), 1699–1703 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Diener HC, Sacco RL et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N. Engl. J. Med.359(12), 1225–1237 (2008).
   PubMed Web of Science ®Google Scholar
• Sandset EC, Bath PM, Boysen G et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST), a randomised, placebo-controlled, double-blind trial. Lancet377(9767), 741–750 (2011).
   PubMed Web of Science ®Google Scholar
• Lam SK, Owen A. Incident diabetes in clinical trials of antihypertensive drugs. Lancet369(9572), 1513–1514 (2007).
   PubMedGoogle Scholar
• Jandeleit-Dahm K, Tikellis C, Reid C et al. Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens.23(3), 463–473 (2005).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens.21(8), 1563–1574 (2003).
   PubMed Web of Science ®Google Scholar
• Preiss D, Zetterstrand S, McMurray JJ et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care32(5), 915–920 (2009).
   PubMedGoogle Scholar
• Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369(9557), 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension51, 393–398 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Ostergreb J, Gerstein H et al.; Candesartan in Heart Failure – Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation112(1), 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Bosh J, Yusuf S, Gerdtein H et al.; DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med.355(15), 1551–1562 (2006).
   PubMedGoogle Scholar
• McMurray JJ, Holman RR, Haffner SM et al.; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med.362(16), 1477–90 (2010).
   PubMed Web of Science ®Google Scholar
• Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann. Intern. Med.151(1), 11–20 (2009).
   PubMed Web of Science ®Google Scholar
• Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in Type 2 diabetes (DIRECT-Protect 2), a randomised placebo-controlled trial. Lancet372(9647), 1385–1393 (2008).
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in Type 1 diabetes: randomised, placebo-controlled trials. Lancet372(9647), 1394–1402 (2008).
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Derosa G; CANDIA (Candesartan and Diuretic vs Amlodipine in Hypertensive Patients) Study Group. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. J. Renin Angiotensin Aldosterone Syst.8(3), 139–144 (2007).
   PubMed Web of Science ®Google Scholar
• Oparil S. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. Am. J. Cardiol.84(10A), 35S–41S (1999).
   Web of Science ®Google Scholar
• Mogensen C, Neldam S, Tikkanen I et al. Randomized controlled trial of dual blockade of rennin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J.321, 1440–1444 (2000).
   PubMed Web of Science ®Google Scholar
• Kincaid-Smith P, Fairley K, Packham D et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet372(9638), 547–553 (2008).
   Google Scholar